Cathie Wood remains incredibly optimistic about the fallen stock, estimating it could surge by up to 170%.
Get Ready to Rake in the Gains with Cathie Wood's Favorite Pick!
Investors, buckle up! The legendary Cathie Wood, known as the disruptor of Wall Street, has set her sights on a stock with potential gains of up to 170%. Yes, you heard it right! Here's the scoop on this once-in-a-lifetime opportunity.
Cathie Wood, the 69-year-old powerhouse, and founder of ARK Invest, has been betting on emerging technologies for years. Her actively managed ETFs were designed for those seeking the potential winners of tomorrow. The latest addition to her portfolio: CRISPR Therapeutics - a company that's revolutionizing gene therapy.
Cathie Wood's Top Pick: CRISPR Therapeutics – A Revolutionary Biotech Giant
Take a peek at the top positions of Wood's flagship ETF, the ARK Innovation ETF, and you'll find CRISPR Therapeutics nestled among the leaders. The company is also one of the largest positions in the ARK Genomic Revolution ETF. And, just to drive the point home, Wood snapped up over 100,000 shares on January 16.
But, what's so special about CRISPR Therapeutics? The company, founded in 2013, is the brainchild of Emmanuelle Charpentier, who won the Nobel Prize in Chemistry in 2020 for developing the groundbreaking gene-editing tool CRISPR/Cas9. This technology has the power to modify DNA, taking biomedicine to unprecedented heights.
CRISPR Therapeutics already has an approved product on the market: Casgevy, a treatment for beta-thalassemia and sickle cell disease. The drug has been approved in the US, UK, and Bahrain, with several promising projects in the pipeline.
The Risks and Rewards of Cathie Wood's Investment
Despite its innovative approach, CRISPR Therapeutics isn't yet profitable, and the stock has lost around 40% over the past year. However, analysts see a favorable entry opportunity, predicting a potential price increase of around 70%. The most optimistic analysts at Piper Sandler have even set a price target of $105 - that's a potential upside of 170%.
Yet, the stock remains risky. Success will depend on whether the company can successfully bring more medications to market. For the cautious investors, ETFs like the ARK Innovation ETF or the ARK Genomic Revolution ETF offer a way to diversify risk while tapping into the potential of disruptive technology.
With CRISPR Therapeutics, Cathie Wood has identified a stock that promises to marry innovation with returns. Whether the optimistic forecasts pan out remains to be seen, but the long-term potential could be enormous.
Also Read: Cathie Wood's Big Bet on AI - Even Nvidia is on Board!
Conflict of Interest Disclosure The publisher, Börsenmedien AG, has a direct interest in CRISPR Therapeutics.
- Cathie Wood's investment in the science and health-and-wellness sector, CRISPR Therapeutics, boasts groundbreaking gene-editing technology that has already produced an approved product for beta-thalassemia and sickle cell disease, with promising projects in the pipeline.
- In the field of technology, CRISPR Therapeutics, a company revolutionizing gene therapy, is effectively integrated into Cathie Wood's portfolios, being a top position in both her ARK Innovation ETF and ARK Genomic Revolution ETF.
- Looking beyond traditional finance, an investment in Cathie Wood's favored stock, CRISPR Therapeutics, offers the potential for significant returns, with some analysts predicting a price increase of up to 170%.
